GlassScriptPhysician profile
Andrew J Genaw
NPI 1285898528
$1,412.32
in general payments reported to CMS, 2019-2025
22 companies · $597 in 2025
The $597 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $207 · 2024: $608 · 2025: $597.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,412.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,412.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $202.42 | 2023-2025 | Rexulti, Nuedexta |
| Neurocrine Biosciences, INC. | $191.61 | 2024-2025 | Ingrezza |
| Abbvie INC. | $168.21 | 2023-2025 | |
| Lilly USA, LLC | $151.65 | 2023-2025 | Mounjaro, Trulicity, Zepbound |
| Aimmune Therapeutics, INC. | $94.12 | 2024-2025 | Zenpep |
| E.R. Squibb & Sons, L.L.C. | $74.67 | 2024-2025 | Eliquis |
| Pfizer INC. | $69.32 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $67.35 | 2023-2024 | Gattex |
| Ucb, INC. | $66.67 | 2025 | Briviact |
| Sanofi-Aventis U.S. LLC | $40.30 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $38.09 | 2024-2025 | |
| Novo Nordisk INC | $37.82 | 2025 | Ozempic |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $33.86 | 2025 | Caplyta |
| Astellas Pharma US INC | $23.95 | 2023 | Veozah |
| Lundbeck LLC | $23.42 | 2025 | Rexulti |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $21.15 | 2024 | Austedo Xr |
| Nestle Healthcare Nutrition INC. | $20.54 | 2023 | |
| Novartis Pharmaceuticals Corporation | $18.46 | 2024 | |
| Janssen Pharmaceuticals, INC | $18.10 | 2024 | Xarelto |
| Axsome Therapeutics, INC. | $17.87 | 2025 | Auvelity |
| Alnylam Pharmaceuticals INC. | $16.39 | 2024 | Onpattro |
| Amneal Pharmaceuticals LLC | $16.35 | 2023 | Rytary |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Genaw listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.